Pockros 2009

Methods	Randomised clinical trial
Participants	244 participants Mean age: 50 years Inclusion criteria: treatment‐naive or prior non‐responders. Exclusion criteria: women who were pregnant or breastfeeding, ALT >/ or = 5 x the ULN, AST >/ or = 5 x the ULN.
Interventions	Experimental group: HCV 796 capsules, 500 mg, every 12 h. daily, 48 weeks (treatment‐naive). HCV 796 capsules, 500 mg, every 12 h daily, 48 weeks (non‐responders). Control group: placebo. Co‐intervention: Peg‐Intron subcutaneous injection, weight‐based dosing, weekly and Rebetol capsules, weight‐based dosing, every 12 h daily for 48 weeks.
Outcomes	Primary outcome complete early virologic response. Secondary outcome rapid virological response.
Notes	We contacted trial authors for addition information on whether HIV participants included, allocation sequence generation and concealment, how was blinding maintained, who was blinded, maximum follow‐up, how many participants dropped out, how was missing data handled, SAE, death, SVR24 but reply not received.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial is described as double‐blinded but the placebo was not described in detail
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The number of dropouts was not described
Selective reporting (reporting bias)	Unclear risk	The outcome called upon in the protocol was reported (NCT00367887)
Vested‐interest bias	High risk	The trial was funded by a company that might have an interest in a given result (PfizerViroPharma)
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias